Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy.

This study has been completed.
Sponsor:
Information provided by:
Celgene Corporation
ClinicalTrials.gov Identifier:
NCT00319969
First received: April 27, 2006
Last updated: September 28, 2009
Last verified: September 2009
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: January 2009
  Primary Completion Date: July 2008 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: September 28, 2009